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Abstract: A potential target for the development of universal vaccine strategies against Influenza A is the M2 protein - a 
membrane protein with a highly conserved extracellular domain. In this study we developed engineered T-cell receptors, 
by fusing M2-specific antibody sequences with T-cell receptor transmembrane and signaling domains to target influenza 
infected cells. When expressed on T-cells, these novel T-cell receptors (chimeric antigen receptors - CARs) are able to 
recognize specific antigens on the surface of target cells via an MHC-independent mechanism. Using an existing 
monoclonal antibody (14C2) specific for the M2 ectodomain (M2e), we generated an M2-specific CAR. We tested the 
specificity of this M2 CAR in vitro by measuring the activation of T-cells in response to M2-specific peptides or M2-
expressing cell lines. Both Jurkat T-cells and peripheral blood mononuclear cells expressing the M2-specific CAR 
responded to specific antigen stimulation by upregulating NFAT and producing ?-interferon. To test whether the M2-
specific CAR are effective at recognizing influenza infected cells in vivo we used an established BALB/c murine infection 
model. At day 4 post-infection, when M2 CAR expressing splenocytes could be detected in the lung, the Influenza 
A/WSN/33 virus titre was around 50% of that in control mice. Although the lung virus titre later increased in the treated 
group, virus was cleared in both groups of mice by day 8. The results provide support for the development of M2e as a 
target for cell mediated immunotherapy. 
Keywords: Antibody, chimeric antigen receptor, influenza A, M2, T-cell, therapy, virus. 
INTRODUCTION 
 Influenza A virus poses a continued threat to the world’s 
population as a result of its pandemic potential and the risk 
of severe influenza A-induced disease with the emergence of 
a pandemic strain. The limited range of antiviral drugs and 
concerns about their effectiveness underscore the importance 
of developing novel treatment. 
 A member of the orthomyxoviridae family, influenza A 
virus genome is comprised of 8 single-stranded negative-
sense RNA segments with an overall size of approximately 
14kb [1]. The virus has an avian reservoir and the potential 
to cause pandemics due to its ability to undergo antigenic 
shift (re-assortment of genetic segments in co-infected cells). 
Influenza A-derived proteins include the surface antigens 
haemagglutinin (H; receptor binding protein) and 
neuraminidase (N; fusion of virus envelope with target cell 
membrane) that are highly variable and define virus strains 
[2]. There are 17 (H1-17) and 9 (N1-9) recognised subtypes 
of the H and N antigens, respectively, and antigenic 
variability results in influenza A epidemics. The N antigens 
have sialidase function that removes sialic acid from 
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glycosilated molecules thereby facilitating release of virus 
during egress from host cell by cleaving glycosidic linkages 
to sialic acid on virion and host cell surfaces. Neuraminidase 
inhibitors (NIs; oseltamivir, zanamivir) block this stage of 
infection [3, 4]. The highly conserved matrix (M) 1 and M2 
proteins form a shell around nucleic material and an ion 
channel in the viral envelope, respectively [5]. The M2 
protein, an abundantly expressed integral membrane protein 
of 97 amino acids has an extracellular domain composed of 
23 non-glycosylated N-terminal residues, the M2 
ectodomain (M2e). M2e is highly conserved across influenza 
A virus. Whilst resistance against the M2 ion channel 
inhibitors (amantadine and rimantadine) is widespread 
amongst avian influenza [6], such resistance is not associated 
with M2e. 
 The immune response to influenza A virus infection 
includes long-lived (serum and nasal secretory) antibody 
responses that are subtype-specific for the infecting virus. 
Neutralising antibodies against H antigens confer resistance 
to infection although re-infection with the same virus can 
occur [7]. Antibodies against the N antigens reduce disease 
severity and transmission risk. Antibodies also arise against 
the M proteins although M2e antibodies are only present in 
low titres. M2e induces a poor antibody response in humans, 
but its conserved nature across influenza A strains and the 
ability of M2e-specific antibodies to restrict virus replication 
in vivo has made it a strong vaccine candidate [8]. Infection 
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also results in cellular immunity mediated by cytotoxic T 
lymphocytes (CTLs) which lyse virus-infected cells. Both H 
and N antigens stimulate CTLs which are key players in 
eradicating and curtailing infection [9]. 
 Avian influenza A gave rise to all known human 
pandemics in the 20
th
 century, and the first pandemic of the 
21
st
 century (‘swine flu’) was a composite of avian, swine 
and human strains that emerged from pigs in Mexico in 
2009. The global population continues to be threatened by a 
new influenza A virus pandemic - and the most likely agent 
is the H5N1 virus. Since its resurgence in 2003, avian 
influenza H5N1 has caused 607 confirmed human cases in 
Asia, the Middle East and Europe (Turkey); to date, 358 
(59%) individuals have succumbed to the infection [10]. 
Whilst H5N1 has all the attributes of a pandemic strain in 
birds (ie, it is a new and virulent strain that transmits 
between birds), it still does not spread efficiently between 
humans. But that may change if the virus adapts to its human 
host. Antiviral therapy is the mainstay of control of H5N1 
influenza infection and antiviral drugs (primarily, the NIs) 
play a key role in current avian influenza preparedness plans. 
The NIs are effective against influenza A if administered 
within 48 hours from onset of clinical symptoms/signs and 
work by inhibiting N antigen-mediated virus egress - but 
avian influenza may need high doses and prolonged 
treatment (‘relative resistance’) which compounds the supply 
of these agents [11]. Furthermore, in light of concerns about 
their effectiveness against H5N1 avian influenza [12, 13] 
and evidence of possible resistance to the drugs, it is of 
paramount importance to develop novel treatment. One such 
approach involves adoptive immunotherapy, and chimeric 
antigen receptor (CAR) technology is one such option. 
 Genetically engineered T cells offer an exciting 
alternative to CTLs. The aim of CAR technology is to 
modify the T cell receptor (TCR) in a manner that replaces 
the antigen recognition part with a single chain antibody-like 
molecule thereby circumventing MHC-restriction and re-
directing CTLs to novel surface targets [14]. The vectors 
may also contain additional molecular machinery (for 
example, lymphocyte triggering receptors TCR-? and FcR-?) 
to enhance homing, cytotoxicity and survival of the 
transfected CTLs to create novel CARs (‘T bodies’). TCRs 
specific for viral antigens have been used previously to re-
direct T cells against virus-infected cells as well as in non-
viral-associated cancer where a tumour-specific surface 
marker is available [15, 16]. The conserved region of the 
M2e protein is exposed on the surface of influenza A virus-
infected cells and is, thus, a potential target for CAR T cells. 
 Originally described by Zebedee and Lamb in 1988, the 
14C2 monoclonal antibody (MAb) recognizes the M2e 
protein [17] and is broadly reactive against several Influenza 
A subtypes. This study delineated the 14C2 antigen 
recognition sequences (paratopes) of the 14C2 hybridoma 
cell line and used the information to develop 14C2 CAR T 
cells that were re-directed to influenza A virus-infected cells. 
Using this novel approach in in vitro and in vivo systems, the 
project generated translational data which will not only be 
applicable to influenza A, but also to other virus infections. 
 
 
MATERIALS AND METHODS 
PBMCs 
 Anonymised buffy coat donations were provided by the 
Scottish National Blood Transfusion Service (SNBTS) from 
registered blood donors with informed consent. Heparin 
(1,000 IU into 50 ml; CP Pharmaceuticals, Wrexham, UK) 
was added to buffy coat samples, and peripheral blood 
mononuclear cells (PBMCs) were separated using 
Histopaque-1077 (Sigma, Irvine, UK). PBMCs were washed 
in RPMI 1640 (Invitrogen), and then cryopreserved in 10% 
dimethyl sulphoxide (Sigma) in foetal bovine serum (FBS; 
Invitrogen). 
Cell Lines and Virus 
 293T/Phoenix Amp retroviral packaging cells (obtained 
from Prof. R Debets; University of Rotterdam), Madin-
Darby canine kidney epithelial cells (MDCK; ATCC), and 
HT1080 cells (ATCC) were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM; Invitrogen) 
supplemented with 10?% FBS (Invitrogen), 100U/ml 
penicillin, 50 ?g/ml streptomycin. The Lymphoblastoid cell 
line LCL114 was derived by in vitro EBV infection of 
PBMCs from healthy donors (Wilkie et al., 2004) and 
cultured in RPMI 1640 (Invitrogen) supplemented with 10% 
FBS (Invitrogen) and 2mM L-glutamine, 100U/ml penicillin, 
50 ?g/ml streptomycin. The A/WSN/33 (H1N1) influenza 
virus, obtained from Dr D. Jackson, University of St 
Andrews, UK, was propagated in MDCK cells prior to use in 
this study. 
Construction of 14C2 CAR 
 The 14C2 Hybridoma cell line was obtained from Prof 
Robert Lamb (University of Illinois) and cultured in RPMI 
1640 supplemented with 1 mM pyruvate, 2mM L-glutamine, 
hybridoma enhancing supplement (Sigma) and 20% FBS 
(Invtrogen). Total RNA was extracted from 1?106 
hybridoma cells using the RNeasy kit from Qiagen and 
treated with DNAse (RNAse deficient - Promega) to remove 
any contaminating DNA. 1 ?g of DNase treated RNA was 
converted to cDNA using oligo dT primers and MMLV 
reverse transcriptase (Affinity Script Multiple Temperature 
cDNA synthesis kit, Stratagene). Using a mouse IgG primer 
set (Calbiochem) the variable heavy and light chain cDNA 
sequences were amplified and cloned into the PGEM-T easy 
vector (Promega). Clones were analysed by sequencing to 
confirm the presence of murine IgG sequences. Variable 
heavy and variable light chain sequences were joined with a 
Serine/Glycine linker to form a ScFv using PCR. The VH 
was amplified using the primers VH forward; 5’- 
ACTGCCATGGCCCAGGTCCAGCTGCAGCAG-‘3 and 
VH reverse; 5’ GCCGCTGCCACCTCCGCCTGAACCGCC 
TCCACCGCTCGAGACAGTGACCAGAGTCCC- ‘3. The 
VL was amplified using VL forward; 5’-TCAGGCGGAG 
GTGGCAGCGGCGGTGGCGGGTCGACGGACATTGTG
ATGACACAGTC-3 and VL reverse; 5’-TTTCTCGTGCG 
GCCGCACGTTTCAGCTCCAACTTGG 3’. Both PCR 
products were purified from a 2% agarose gel, 50 ?g of each 
mixed together, annealed at 65°C, and subject to 5 rounds of  
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PCR before the addition of the VH forward primer and the VL 
reverse primer to amplify the full length product (Fig. 1A). 
The 14C2 ScFv PCR product was cloned into the retroviral 
vector PMP71.tCD34.2A.CD19.CD3zeta [18] (Fig. 1B) by 
replacing the CD19 encoding sequence by digestion with 
ClaI and NotI. 
Peptides 
 All peptides were synthesised by Thistle Scientific 
(Scotland). Three M2 specific peptides were used: 
 M2 terminal peptide; SLLTEVETP, 
 M2e; SLLTEVETPIRNEWGCRCNDSSD, and 
 M2 tetramer; SLLTEVETPIRNEWGCRCNDSSDGGG]4 
-(branched K). 
 An unrelated peptide LIALWNLHGQALFLG (LMP-1) 
was used as a negative control. 
Transduction of Human PBMCs 
 The packaging cells (293T/Phoenix-Amp) were seeded at 
1.5?106 cells per 75 cm2 flask coated with 0.1% gelatin/PBS 
and grown overnight at 37°C in 10 ml DMEM (10% FBS, 
100U/ml penicillin, 50 ?g/ml streptomycin, 2mM L-
Glutamine). The following day, the media was refreshed 3 
hours prior to transfection of the cells. PBMCs (from frozen 
stock) were resuspended in RPMI (20% FBS, 100U/ml 
penicillin, 50 ?g/ml streptomycin, 2mM L-Glutamine) at a 
cell density of 2?106/ml, and stimulated with OKT3 (anti-
CD3 MAb) to a final concentration of 10 ng/ml, for 2 days 
(37°C/5% CO2). The packaging cell line was transfected 
with the 14C2 retroviral CAR construct and helper 
constructs pHIT60 and pColtGalV (provided by Prof R 
Debets, University of Rotterdam) (10 ?g of each) to a total 
amount of 40 ?g DNA, using the Calcium Phosphate 
transfection kit (Promega). Cells were incubated for 2 days 
(37°C/5% CO2). Retrovirus was harvested from the 
transfected packaging cells and used to infect activated 
PBMCs. The virus supernatant was filtered through a 0.45 
?m filter and IL-2 added to a final concentration of 100 
IU/ml. 2 mls of virus was added to each well of a Non-tissue 
culture 24-well plate previously coated with retronectin (12 
?g/ml in dH2O; Takara, Cambrex), and centrifuged for 1 
hour at 1000?g. Following centrifugation the supernatant 
was removed and 1?106 activated PBMCs were then added 
per well. The cells were then centrifuged for 1 hour at 
1000?g and incubated 4-5 hours (37°C/5% CO2). The media 
was aspirated carefully from the wells and followed by 
addition of 2 ml RPMI (20% FBS, 100U/ml penicillin, 50 
?g/ml streptomycin, 2mM L-Glutamine, 100 IU/ml IL-2) 
and incubated overnight (37°C/5% CO2). Transduction 
efficiency was assessed at day 4 post transduction, using a 
CD34 specific antibody (Becton Dickinson; clone 582) to 
measure the expression of tCD34 on the surface of 
transduced cells using flow cytometry. 
Transduction of Murine Splenocytes 
 The packaging cells (293T/Phoenix Amp) were prepared 
and transfected as above except that the pColtGalV plasmid 
was replaced with pHIT123 (MLV-E Env, provided by Prof. 
R. Debets, University of Rotterdam). Spleens were isolated 
from Balb/c mice and passed through a 70 μm cell strainer 
into a 50 ml tube using 20mls of PBS. The harvested 
splenocytes were centrifuged, resuspended in 5 ml of filtered 
erylysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM 
EDTA, pH 7.4) and incubated for 4 min at 4°C. The cells 
were then washed twice in 20 ml of RPMI 1640 medium, 
before resuspending in 30 ml RPMI 1640 medium (+10% 
FBS, 100U/ml penicillin, 50 ?g/ml streptomycin, 2mM L-
Glutamine, 1 mM NaPyruvate, 50 μM ?-mercaptoethanol) 
and counted. Splenocytes were seeded at 5x10
6
/ml in a T25 
flask before addition of 2.5 μg/ml Concanavalin A 
(Calbiochem), 1ng/ml IL-7 (Santa Cruz) and 100 U/ml 
human rIL-2, and incubated for 24 hours. The activated 
splenocytes were then transduced with retrovirus harvested 
from the packaging cells using retronectin coated plates as 
described above. The transduced splenocytes were cultured 
in fresh culture media with 100 U/ml IL-2, at a cell density 
of 0.15?106/ml in 2 ml per well of a 24 well plate for 2 days 
before being assessed for transduction efficiency using flow 
cytometry and a CD34 antibody. 
Flow Cytometry 
 Cells to be analysed were washed twice in PBSA (1% 
BSA, 0.1% sodium azide, 0.2% EDTA) by centrifugation at 
120?g for 5 minutes. The supernatant was decanted and cells 
resuspended in residual liquid. 10?L of the anti-CD34 (clone 
582) antibody was added and the tubes incubated for 20 
minutes at 4°C in the dark. Cells were washed twice in 
PBSA then resuspended in 1x CellFix (Becton Dickinson) 
and evaluated on a FACScan (Becton Dickinson) flow 
 
Fig. (1). (A) Amino acid sequence of 14C2 ScFv. The Heavy and light variable chains are joined using a flexible Serine/Glycine linker 
sequence (bold). (B) Retroviral vector construct used to express the 14C2 ScFv. 
tCD34 ScFv 2a CD3zeta LTR LTR Intron 
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cytometer. At least 10,000 events were acquired for each 
sample. Data were subsequently analysed using the 
CellQuest software. 
M2 Expressing Cell Lines 
 The following oligonucleotides were annealed and 
subject to PCR to generate a dsDNA encoding the Influenza 
M2 protein with a deletion of residues 29-31 and 62: 
 5’CGGGATCCATGAGTCTTCTAACCGAGGTCGAAA 
CGCCTATCAGAAACGAATGGGGGTGCAGATGCAACG 
ATTCAAGTGATCCTCTCGTCATTATCATTGAGATCTT 
GC-3’ and 5’-TGCCTCGAGTAGTTTTTTATCTTTTC AA 
ACCGTATTTAAAGCGACGATAAATGCATTTGAAAAA 
AAGACGATCAAGAATCCACAATATCAAGTGCAAGAT 
CTCAATGATAATGACG-3’. The DNA was cloned into 
the retroviral expression vector pFB-Neo (Stratagene) using 
the restriction enzymes BamHI and XhoI. Recombinant 
retrovirus was produced by transfecting the pFB-Neo M2 
plasmid into the packaging cells (293T/Phoenix Amp) as 
described for transduction of human PBMCs. The resulting 
retrovirus was then used to transduce the cell lines HT1080 
and LCL114 (EBV transformed Lymphoblastoid cells line). 
Expression of the M2 protein was confirmed by staining 
with the 14C2 Monoclonal antibody (Fig. 2). 
ELISPOT 
 The Elispot technique is an established assay used to 
determine the number of ?-IFN releasing cells. Using 
PBMCs transduced with the M2 specific CAR, we used the 
ELISPOT assay to determine the number of ?-IFN releasing 
cells in response to specific stimulation with M2 peptides or 
M2 expressing cell lines. Briefly, 0.2x10
6 
14C2 CAR 
transduced PBMCs in 100?l of culture media were 
stimulated with 10?l peptide (100?g/ml) or 0.1x106 M2 
expressing LCL114 for 24 hours, and assayed for the 
expression of gamma interferon according to manufacturers 
instructions (Mabtech). 
T-Cell Activation Assay - NFAT Reporter Assay 
 5?106 Jurkat E6.1 T cells were transiently nucleofected 
with 5 μg GLuc-NFAT(RE)6 and 5 μg of 14C2 CAR 
construct using an Amaxa nucleofector (AmaxaBiosystems, 
Cologne, Germany) as described [19]. Briefly, T cells were 
resuspended in 100 μl supplemented buffer V to which was 
added and pulsed with the Nucleofector set at program C-16. 
Next, T cells were immediately transferred to 2.5 ml warm 
Jurkat T-cell medium in T25 flasks for overnight recovery 
(37°C, 5% CO2). 0.2 ?106 transfected Jurkat T-cells were 
transferred to each well of a 96 well plate and stimulated 
with peptides (1?g/ml) or 0.1?106 M2 expressing cell lines 
 
Fig. (2). Expression of Influenza M2 in cell lines HT1080 and LCL114. Cells were transduced with retroviral construct expressing a deletion 
variant of M2 (?29-31, ?62), that is less cytotoxic (A and B), or an empty retroviral construct (C and D). M2 was stained with the 14C2 
monoclonal antibody and an anti-mouse HRP. 
HT1080 LCL114 
A B 
D C 
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for 24 hours. Subsequently, 25 ?l of cell supernatant was 
assayed for luciferase activity according to manufacturer`s 
instructions (Gluc substrate; New England Biolabs) using a 
Turner systems Luminometer. 
Mouse Model of Influenza Virus Infection 
 BALB/c mice were purchased from Harlan UK Ltd 
(Oxon, UK). All work was carried out under a UK Home 
Office licence according to the Animals (Scientific 
Procedures) Act 1986. Ten-week-old female mice were used 
in all experiments. Mice were anaesthetized using halothane 
(Rhone Merieux Ltd) and 1?106 transduced murine 
splenocytes were transferred to each mouse via the tail vein. 
24 hrs after the transfer of transduced splenocytes, the mice 
were anaesthetized and infected intranasally with 5?102 
p.f.u. of A/WSN/33 influenza virus in 40 ?l PBS volume. 
Mice were weighed daily and assessed for visual signs of 
clinical disease, including inactivity, ruffled fur and laboured 
breathing. At this virus dose, animals do not exhibit clinical 
signs or weight loss. At various times after infection, mice 
were euthanized by CO2 asphyxiation, and the lungs 
removed, homogenized in PBS and clarified by 
centrifugation. Titres of infectious virus were determined by 
standard plaque assays on MDCK cells. 
tCD34 PCR 
 DNA was extracted from lung tissue using the DNeasy 
blood and tissue DNA kit, according to manufacturers 
instructions (Qiagen). 100?g of extracted DNA was 
amplified using a nested PCR protocol with tCD34 specific 
primers (1
st
 round amplification: 5’-CAAGCCCTATACC 
TCCTCTT-3’ and 5’-GTGTTTTCTGGCTGTAGCTC-3’, 
2
nd
 round amplification: 5’-CTGCGCCGAGTTTAAGAAA 
G-3’ and 5’-TGCTCGGTAAAGTCCAGGAT-3’) or murine 
GAPDH primers (5’-GCCCATCACCATCTTCCAG-3’ and 
5’-TGAGCCCTTCCACAATGCC-3’). 
Statistical Analysis 
 Data were analysed using Graphpad Prism software (San 
Diego, CA). For the mouse infection experiments data were 
analysed using a two-way Anova with Bonferoni post-tests. 
RESULTS 
Generation of M2 Specific ScFv 
 The M2e-specific 14C2 mAb was generated using M2 
protein purified from A/WSN/33-infected CV1 cell lysates 
[17]. The antibody-binding site was located to the M2 
ectodomain (M2e). Using the Hybridoma cell line (Prof RA 
Lamb, Northwestern University, Illinois, USA), we 
amplified the MAb variable chain regions and joined them 
together with a Serine/Glycine spacer sequence using PCR. 
The sequence of the resulting Single chain antibody (ScFv) 
is shown in Fig. (1A). 
Construction of M2 Specific Chimeric Antigen Receptor 
 The 14C2 ScFv sequence was cloned into a retroviral 
expression vector [18]. This construct (Fig. 1B) places the 
ScFv sequence in frame with the T-cell receptor zeta chain 
transmembrane and signalling domain. The construct also 
encodes a truncated/inactive form of CD34 (tCD34) which  
 
acts as a marker of transduction. Both the tCD34 and 14C2 
CAR were separated by the 2A protease signal from 
Encephalomyocarditis virus (EMCV), which cleaves the 
two proteins. 
Testing Specificity of M2 CARs In Vitro 
 Two in vitro assays were used to determine the 
specificity of the two M2 CAR constructs. Firstly, an NFAT 
reporter assay [19], which is based on the fact that when T-
cells become activated (through recognition of specific 
antigens), the NFAT transcription factor is upregulated and 
activated. This can then be measured through its ability to 
activate a luciferase reporter gene under the control of NFAT 
control sequences. The M2 CAR construct was transfected 
into Jurkat T-cells along with a NFAT luciferase reporter 
plasmid. These Jurkat T-cells were then exposed to M2 
specific peptides, or M2 expressing cells (HT1080), and the 
luciferase activity measured in the supernatant. As shown in 
Fig. (3A), the 14C2 ScFv CAR resulted in NFAT activation 
when cells were stimulated with M2e and M2 tetramer 
peptides, but not with an irrelevant peptide (LMP-1). 
Significant activation of NFAT in response to M2 expressed 
on the surface of the HT1080 cell line (Fig. 2) was also 
observed (Fig. 3B). 
 In a second assay, the ELISPOT technique was used to 
further confirm the specific activation of T-cells with our 
14C2 CAR construct in response to stimulation with M2. 
The ELISPOT assay detects the secretion of ?-Interferon (?-
IFN) from activated T-cells. This assay is quantitative since 
the ?-IFN produced from each activated T-cell is visualised 
as a spot on a membrane in a multi-well plate. These spots 
can be counted and represent the number of activated T-cells 
in a given population. Human PBMCs were transduced with 
the retroviral construct encoding the 14C2 CAR. The 
transduction efficiency as determined by tCD34 expression 
was 72.5% (data not shown). The transduced PBMCs were 
then assayed using ELISPOT for ?-IFN production upon 
stimulation with either M2 peptides or an M2 expressing 
LCL cell line (LCL114). As shown in Fig. (4), significant 
numbers of transduced T-cells were specifically activated (as 
measured by ?-IFN release) in response to the specific M2 
stimulus. 
M2 CAR Mediated Control of Virus Titres in an In Vivo 
Model 
 After successfully showing in vitro that the 14C2 CAR 
was able to recognise and specifically activate transduced T-
cells in response to M2 stimulation, 14C2 CAR transduced 
T-cells were assessed for their ability to modulate virus 
replication in BALB/c mice infected with the mouse adapted 
strain of influenza virus A/WSN/33. 
 Splenocytes were prepared from BALB/c spleens, 
activated by stimulation with anti-CD3 antibody, 
Concanavalin-A and IL-7, and transduced with the retroviral 
construct encoding 14C2 ScFv CAR. Transduction 
efficiency was measured though the expression of tCD34 at 
88.5% (data not shown). As a control, splenocytes were also 
transduced with an empty retroviral construct (mock cells). 
One week post-transduction, the splenocytes (10
6
 cells per 
mouse) were administered intravenously (IV) via the tail  
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Fig. (3). Activation of NFAT in Jurkat T-cells in response to (A) peptide stimulation and (B) stimulation with M2 expressing HT1080 cells. 
Jurkat cells were transfected with the 14C2 CAR construct and a NFAT luciferase reporter construct. After stimulation with peptides or M2 
expressing cells for 24 hours, the amount of Gaussia Luciferase secreted into the media was quantified (Relative light units - RLU). 
Experiments were performed in triplicate. Error bars represent the standard deviation of the mean. 
 
Fig. (4). ELISPOT assay measuring the number of ?-IFN expressing PBMCs after stimulation for 24 hours with (A) M2 specific peptides, 
and (B) with M2 expressing LCL114 cell line. Experiments were performed in triplicate. Error bars represent the standard deviation of the 
mean. 
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vein. One day following the IV transfer of the cells the mice 
were infected intranasally with 500pfu of Influenza 
A/WSN/33. Mice were weighed daily, but showed no 
significant changes in weight during the course of the 
experiment (data not shown). On days 2, 4, 6 and 8 pi, 
groups of 4 mice were sacrificed and lungs removed for 
titration of virus. The data shown in Fig. (5) indicate that in 
mice receiving the mock transduced splenocytes, A/WSN/33 
lung titres increased up to a peak on day 4, before being 
cleared by day 8. Mice receiving 14C2 M2 CAR transduced 
splenocytes, however, had a significantly reduced virus lung 
titre on day 4 (p<0.001), but a higher viral lung titre on day 6 
(p<0.001), before being cleared by day 8. H&E staining of 
lung section revealed significant lymphocyte infiltration and 
inflammation of the lungs on days 2, 4, and 6 post infection 
for both 14C2 CAR treated mice and mock treated mice 
(Fig. 6). The presence of tCD34 sequences could be detected 
in the lungs of 14C2 CAR treated mice by nested PCR on 
days 2 and 4 post infection (days 3 and 5 post infusion; Fig. 
7), indicating the presence of 14C2 CAR transduced 
lymphocytes. 
Fig. (5). Titres of Influenza virus A/WSN/33 in the lungs of 
infected Balb/c mice infused IV with 1?106 14C2 CAR transduced 
spelonocytes or mock transduced splenocytes. Transduced 
splenocytes were transferred to the mice 1 day before intranasal 
infection with 500pfu of A/WSN/33. Groups of four mice were 
sacrificed on days 2, 4, 6, and 8 pi, and the viral titre determined in 
the lung by plaque assay. For days 4 and 6pi there is a statistical 
difference between lung titres in mock treated versus 14C2 CAR 
treated mice (p<0.001). Virus titres were zero on day 8 pi for both 
14C2 CAR and mock treated mice. These data are representative of 
two independent experiments. 
DISCUSSION 
 Influenza A virus poses a continued threat to the world’s 
population as a result of its pandemic potential and the risk 
of severe influenza A-induced disease with the emergence of 
a pandemic strain. Limited range of antiviral drugs and 
concerns about their effectiveness underscore the importance 
of developing novel treatment and alternative vaccine 
strategies. This study aimed to provide evidence that 
redirecting the T-cell response against the conserved M2e 
protein of Influenza virus could provide a therapeutic option 
or contribute to the design of a universal vaccine against 
multiple Influenza strains. 
 We generated a Chimeric antigen receptor (CAR) derived 
from an existing (14C2) hybridoma cell line. The 14C2 
monoclonal antibody was produced against the M2e domain  
 
from the Influenza A/WSN/33 strain, but is broadly reactive 
against other Influenza A strains [17]. When transduced into 
human T lymphocytes, 14C2 CAR T cells were activated by 
the M2e target as assessed by NFAT upregulation and 
interferon-? production upon encounter in vitro with M2-
specific peptides or M2-expressing cell lines (Figs. 3, 4). In 
the context of transduced murine splenocytes, the 14C2 CAR 
delayed peak influenza A titres in lungs of Balb/c mice 
infected with influenza A/WSN/33 as a small animal model 
[20, 21] of virus infection (Fig. 5). The lower titres of virus 
in the lungs on day 4 correlated to the presence of 14C2 
CAR transduced splenocytes (Fig. 7). Although in this model 
using relatively low titres of Influenza virus, clinical signs of 
infection (i.e. weight loss) are not observed, the significant 
reduction in viral lung titres and delay in peak replication 
may give the immune system additional time to prevent a 
lethal outcome. A vaccine strategy which could induce both 
a cell mediated and humoral response to the M2e protein 
could elicit broad immunity across the different strains of 
Influenza. 
 A recent study [22] has shown that the expression of an 
alternative form of M2 by the Influenza A/WSN/33 strain 
could allow it to escape neutralization by the 14C2 antibody. 
Specific immune pressure against the M2 protein by the 
14C2 CAR splenocytes may therefore reduce viral titres at 
early time points, but increased expression of alternative 
forms of M2 (not recognized by 14C2) could allow the virus 
to escape immune destruction at later times post infection. 
 The M2e domain has been extensively investigated as a 
suitable target for a vaccine that could be universally 
applicable to all influenza A virus strains (including H5N1) 
because of its highly conserved sequence [23-25]. Already, 
clinical studies using candidate M2e-based vaccines have 
demonstrated immunogenicity and safety in humans [26, 27] 
although some concerns remain as the neutralizing ability of 
M2e-specific antibodies in humans despite encouraging 
cross-protective effects observed in animal models [28]. In 
contrast, the use of CAR T cells has focused on their use in 
adoptive immunotherapy against tumor targets including 
virus-associated cancers [29, 30] rather than treatment for 
acute viral infections such as influenza A. However, our 
approach provides evidence that redirecting T-cells to 
Influenza infected cells limits the severity of the infection. 
 Our results are not only applicable to all influenza A 
virus strains but also to other virus infections. Future studies 
are required to characterize the in vivo effect observed in our 
study and assess the interactions between M2e-specific 
CARs and influenza A-infected cells in the lung with a view 
to refine the approach to therapy. Key to such studies is 
delineation of the immune response to influenza A infection 
and the manner in which such infection may derail host 
defenses resulting in the ‘cytokine storm’ phenomenon. It is 
interesting to note that SCID mice are actually less 
susceptible to infection with Influenza virus, emphasizing 
the role of an intact immune system in the pathogenesis of 
infection [31]. 
 Taken together, we have provided data showing that 
M2e-specific CAR T-cells can be generated and showed 
their effectiveness in in vitro and in vivo models. The results  
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Fig. (7). Detecting the presence of tCD34 sequences in mouse lung 
cell homogenates using a nested PCR assay. tCD34 sequences were 
present on days 2 and 4 post infection (days 3 and 5 post infusion of 
14C2 CAR splenocytes). (tCD34, 240bp, GAPDH, 407bp). 
support further development M2e as a target for cellular and 
humoral immunotherapy as a universal treatment for 
influenza A virus infection and disease. 
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Fig. (6). H&E staining of lung sections taken at day 0, 2, 4, 6 and 8 post infection. Significant inflammation and lymphocyte infiltration is 
observed on days 2, 4, and 6 pi. 
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